Zymeworks Gross Profit 2016-2021 | ZYME

Zymeworks gross profit from 2016 to 2021. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
Zymeworks Annual Gross Profit
(Millions of US $)
2020 $-130
2019 $-86
2018 $-4
2017 $10
2016 $-26
2015 $-15
Zymeworks Quarterly Gross Profit
(Millions of US $)
2021-09-30 $-45
2021-06-30 $-49
2021-03-31 $-44
2020-12-31 $-22
2020-09-30 $-52
2020-06-30 $-27
2020-03-31 $-29
2019-12-31 $-44
2019-09-30 $-21
2019-06-30 $-16
2019-03-31 $-6
2018-12-31 $15
2018-09-30 $-12
2018-06-30 $7
2018-03-31 $-13
2017-12-31 $37
2017-09-30 $-11
2017-06-30 $-7
2017-03-31 $-9
2016-12-31 $-7
2016-09-30 $-8
2016-06-30 $-4
2016-03-31 $-8
2015-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.861B $0.039B
Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.010B 7.90
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.357B 20.93
Biohaven Pharmaceutical Holding (BHVN) United States $6.783B 0.00
Arcus Biosciences (RCUS) United States $3.105B 0.00
Emergent Biosolutions (EBS) United States $2.254B 8.10
ADC Therapeutics SA (ADCT) Switzerland $1.478B 0.00
Myovant Sciences (MYOV) United Kingdom $1.368B 0.00
Ambrx Biopharma (AMAM) United States $0.337B 0.00
SQZ Biotechnologies (SQZ) United States $0.319B 0.00
Enzo Biochem (ENZ) United States $0.162B 15.90